Anti-Human CTLA-4 (Ipilimumab Biosimilar)
Catalog #500034
| Cat # | Size | Price | Quantity | |
|---|---|---|---|---|
| 500034 | 1 mg | $200.00 | ||
| 500034 | 5 mg | $600.00 | ||
| 500034 | 20 mg | $1,250.00 |
Product Details
Ipilimumab biosimilar is a recombinant fully human IgG1 monoclonal antibody designed to target cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), a key immune checkpoint molecule. Like the original Ipilimumab (marketed as Yervoy), the biosimilar blocks CTLA-4, enhancing T-cell activation and promoting an immune response against tumors. It is primarily used in cancer immunotherapy, particularly for melanoma and other malignancies.
Specifications
| Clone | Ipilimumab |
|---|---|
| Reactivities | Human |
| Isotype | Human IgG1 |
| Recommended Isotype Control | Human IgG1 isotype control |
| Format | Liquid |
| Formluation | PBS, pH 7.0 |
| Sterility | 0.2 µm filtered |
| Clonality | Recombinant |
| Conjugation | Unconjugated |
| Immunogen | Human CTLA-4 |
| Host | CHO cells |
| Purity | >95% (HPLC, SDS-PAGE) |
| Endotoxin | < 1.0 EU/mg (LAL assay) |
| Grade | In vivo ready (RUO) |
| Application | Neutralization; Flow Cytometry; ELISA; WB |
| Purification | Protein A |
| Storage Conditions | 2-8 °C, Avoid freeze / thaw cycle |
| Shelf Life | 6 months |
| Regulatory Status | RUO |